CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--$KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided a development update on its oral plasma kallikrein inhibitor portfolio. "In December we filed with regulatory authorities to begin our Phase 2 study of KVD900 as a potential oral acute treatment for hereditary angioedema, or HAE. As previous